Hepatitis B virus (HBV) specifically infects hepatocytes and causes severe liver diseases.
The HBV life cycle is unique in that the genomic DNA (relaxed-circular partially double …

During the last forty years we have witnessed impressive advances in the field of antiviral
drug discovery culminating with the introduction of therapies able to stop human …

Background & Aims Current antiviral therapies help keep HBV under control, but they are
not curative, as they are unable to eliminate the intracellular viral replication intermediate …

Hepatitis B virus (HBV) infection remains a major public health concern worldwide with
about 257 million individuals chronically infected. Current therapies can effectively control …

Hepatitis B virus (HBV) is a highly contagious pathogen that afflicts over a third of the world's
population, resulting in close to a million deaths annually. The formation and persistence of …

Hepatitis B is a potentially deadly liver infection caused by the hepatitis B virus. It is a serious
public health problem globally. Substantial efforts have been made to apply machine …

Interferon (IFN) stimulates a whole repertoire of cellular genes, collectively referred to as
ISGs (Interferon-stimulated genes). ISG20, a 3´-5´ exonuclease enzyme, has been …

Background and Aims Epitranscriptomic modification of RNA has emerged as the most
prevalent form of regulation of gene expression that affects development, differentiation …

Chronic hepatitis B virus (HBV) infections are one of the leading causes of cirrhosis and
hepatocellular carcinoma. N6-methyladenosine (m6A) modification of cellular and viral …

“Functional cure” is being pursued as the ultimate endpoint of antiviral treatment in chronic
hepatitis B (CHB), which is characterized by loss of HBsAg whether or not anti-HBs …